Dariusz M. Kowalski

TL;DR: Roniciclib combined with chemotherapy demonstrated an unfavorable risk‐benefit profile in patients with extensive‐disease SCLC, and the study was prematurely terminated.

TL;DR: This is the first, single institution study that estimates the EGFR mutation incidence in the Polish population and finds the strongest clinicopathological correlation with the EGfr mutation was found for histological type, gender, and FISH positive result.

TL;DR: Cytological and small biopsy samples with low content of tumor cells and specimens from metastatic lesions are a sufficient source for EGFR mutation testing in NSCLC patients and the incidence of EGFR gene mutations was similar to those reported in other Caucasian populations.

TL;DR: awareness of all possible cardiovascular complications in NSCLC encourages vigilance in early diagnostics and treatment, and Cytotoxic agents and anti-VEGF inhibitors mainly cause vascular complications, including venous or arterial TE.

TL;DR: Pembro plus chemo provided clinical benefit for pts with NSCLC pts, regardless of presence/absence of stable brain metastases, and the toxicity profile was manageable.